A systematic monthly value screen highlights five stocks—PulteGroup, Deckers Outdoor, EOG Resources, CF Industries, and ResMed—as undervalued on DCF and quality metrics despite an AI-focused market.
PHM — LONG The author's January systematic value screen selects PulteGroup (PHM) as a long, citing 8.8x earnings, 77% DCF upside, 21% ROE, 15% margins and minimal debt. The argument is that the homebuilder is a high-quality, profitable company trading at a low valuation relative to its DCF-derived fair value.
PulteGroup (PHM) scored 8.3/10. Trading at 8.8x earnings with 77% DCF upside. The homebuilder posts 21% ROE with 15% margins and minimal debt. Low valuation despite solid profitability.
DECK — LONG The author's screen selects Deckers Outdoor (DECK) as a long, highlighting the highest quality score at 34/35, 15.2x earnings, 104% upside to fair value, 40% ROE and 19% margins. The claim is that DECK combines high quality and profitability with a valuation below the screen's fair-value estimate.
Deckers Outdoor (DECK) came in at 8.2/10. This one had the highest quality score at 34/35 points. Trading at 15.2x with 104% upside to fair value. Posting 40% ROE and 19% margins.
EOG — LONG The author's January value screen selects EOG Resources (EOG) as a long, citing 10.3x earnings, 81% upside, and 24% margins with conservative leverage. The argument is that the energy producer is undervalued despite profitable margins and low leverage.
EOG Resources (EOG) scored 8.0/10. Energy at 10.3x earnings with 81% upside. Posts 24% margins with conservative leverage.
CF — LONG The author's January value screen selects CF Industries (CF) as a long, noting 9x earnings, 90% DCF upside, 28% ROE, 20% margins and a depressed valuation for an essential product. The claim is that the nitrogen fertilizer producer is undervalued relative to its cash-flow potential and profitability.
CF Industries (CF) at 7.9/10. Nitrogen fertilizer producer trading at 9x earnings with 90% DCF upside. Shows 28% ROE and 20% margins. Essential product with depressed valuation.
RMD — LONG The author's January value screen selects ResMed (RMD) as a long, arguing that 25% ROE and 27% margins justify its 24.5x multiple under sector-relative scoring. The claim is that the medical-device maker is a quality value pick despite the optically high P/E.
ResMed (RMD) rounds out the list at 7.7/10. Medical devices. Trading at 24.5x, which looks high until you see 25% ROE and 27% margins. The sector-relative scoring recognizes that healthcare companies with these metrics justify premium multiples.